(Q43180448)

15 November 2017

title

Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS). (English)

1 reference

15 November 2017

1

1 reference

15 November 2017

R Kälviäinen

2

1 reference

15 November 2017

F Von Raison

3

1 reference

15 November 2017

S Giordano

4

1 reference

15 November 2017

B Emir

5

1 reference

15 November 2017

K Chatamra

6

1 reference

15 November 2017

publication date

25 January 2010

1 reference

European Journal of Neurology

15 November 2017

published in

1 reference

15 November 2017

volume

17

1 reference

15 November 2017

issue

5

1 reference

15 November 2017

page(s)

726-732

1 reference

Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Pregabalin pharmacology and its relevance to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Auxiliary subunits: essential components of the voltage-gated calcium channel complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Defining success in clinical trials--profiling pregabalin, the newest AED.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Pregabalin as adjunctive therapy for partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Proof of efficacy trials: endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Sleep disturbances reported by refractory partial-onset epilepsy patients receiving polytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

Psychometric properties of the Medical Outcomes Study Sleep measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02916.X

10.1111/J.1468-1331.2009.02916.X

21 January 2018

Identifiers

DOI

1 reference

15 November 2017

1 reference